KalVista defies sales expectations again for Ekterlynews2025-11-11T14:51:41+00:00November 11th, 2025|Endpoints News|
Fabric buys UCM Digital Health in fifth acquisition in three yearsnews2025-11-11T14:00:44+00:00November 11th, 2025|Endpoints News|
EnGene posts more pivotal data for bladder cancer gene therapy, plans 2026 filingnews2025-11-11T12:30:20+00:00November 11th, 2025|Endpoints News|
Neurocrine reports Phase 2 fail for depression drug it licensed from Takedanews2025-11-11T11:40:18+00:00November 11th, 2025|Endpoints News|
Jury gives Novo Nordisk a win in decade-long hemophilia fraud casenews2025-11-10T20:44:45+00:00November 10th, 2025|Endpoints News|
FDA seeks to remove warnings from labels of hormone therapies for menopausenews2025-11-10T20:21:16+00:00November 10th, 2025|Endpoints News|
#AHA25: Novo Nordisk posts mixed mid-stage data on ATTR-CM drugnews2025-11-10T20:00:37+00:00November 10th, 2025|Endpoints News|
Cogent soars on back of Phase 3 success in stromal tumorsnews2025-11-10T16:30:46+00:00November 10th, 2025|Endpoints News|
AnaptysBio reports Phase 2 fail in ulcerative colitis; Lyell’s CAR-T licensing dealnews2025-11-10T16:14:00+00:00November 10th, 2025|Endpoints News|
